Sodium-Glucose Cotransporter 2 Inhibitors Should Be Avoided for the Inpatient Management of Hyperglycemia
Authors' conclusion
Although SGLT2i are a preferred pharmacotherapy class for the outpatient management of type 2 diabetes mellitus, there are considerable safety concerns when using them in a hospital setting, and avoidance is recommended.
Study context
- Population
- Hospitalized patients with T2D and hyperglycemia; studies of inpatient SGLT2i use (PubMed, Google Scholar; English only)48 articles
- Comparison
- SGLT2i vs DPP-4i for inpatient hyperglycaemia
- Outcome
- Risks of inpatient SGLT2i use
Main finding
As reported in the abstract
- Significant safety concerns with SGLT2i for inpatient management of hyperglycemia
Further findings
- Head-to-head, SGLT2i not more effective for inpatient glycemic control than DPP-4i
- SGLT2i did not reduce insulin requirements when combined with insulin
Original publication
Sodium-Glucose Cotransporter 2 Inhibitors Should Be Avoided for the Inpatient Management of Hyperglycemia. Endocr Pract. Published 10 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →